Physician profile
Robert L Rusche
NPI 1437152808
$2,783.15
in general payments reported to CMS, 2019-2025
35 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $236 · 2021: $144 · 2022: $207 · 2023: $632 · 2024: $562 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $301.82 | 2019-2025 | |
| Amgen INC. | $284.46 | 2019-2024 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $266.79 | 2021-2025 | Verquvo, Belsomra, Zerbaxa |
| Glaxosmithkline, LLC. | $180.16 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $169.11 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $155.59 | 2023-2025 | Gemtesa, Myfembree |
| Otsuka America Pharmaceutical, INC. | $141.74 | 2023-2025 | Rexulti |
| Lundbeck LLC | $98.24 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.51 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $87.57 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Mylan Specialty L.P. | $68.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $67.62 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $45.63 | 2024-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $44.66 | 2024-2025 | Auvelity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $36.34 | 2023 | Vraylar, Linzess |
| Sanofi-Aventis U.S. LLC | $32.14 | 2022-2023 | |
| Amarin Pharma, INC. | $30.00 | 2020 | |
| Ge Healthcare | $28.07 | 2024 | |
| Dexcom, INC. | $27.31 | 2023-2025 | Dexcom G6 Transmitter |
| Tactile Systems Technology INC | $24.09 | 2019 | |
| Xeris Pharmaceuticals, INC. | $23.92 | 2023 | Gvoke Hypopen |
| Insulet Corporation | $23.86 | 2025 | Omnipod |
| Boston Scientific Corporation | $23.09 | 2025 | Watchman Flx |
| Hologic Sales and Service, LLC | $22.89 | 2023 | Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $22.86 | 2023 | Veozah |
| Vanda Pharmaceuticals INC. | $21.54 | 2020 | |
| Viatris Specialty LLC | $20.61 | 2025 | Yupelri |
| Nestle Healthcare Nutrition INC. | $20.51 | 2023 | |
| Esperion Therapeutics, INC. | $18.12 | 2025 | Nexletol |
| Kci USA, INC. | $17.64 | 2019 | |
| Antares Pharma, INC. | $16.14 | 2023 | Xyosted, Tlando, Nocdurna |
| Inspire Medical Systems, INC. | $13.78 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $13.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.49 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rusche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.